首页 › 卵巢癌 › 俄亥俄州 › Cincinnati
Cincinnati OH 卵巢癌临床试验
19项针对 卵巢癌的研究正在 Cincinnati及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Good Samaritan Hospital - Cincinnati, Cincinnati
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
招募中2 期
- University of Cincinnati Medical Center. /ID# 278925, Cincinnati
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
招募中2 期
- Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
招募中2 期
- Research Site, Cincinnati
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- University of Cincinnati Medical Center, Cincinnati
- Oncology Hematology Care Inc, Cincinnati
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
招募中3 期
- University of Cincinnati Medical Center ( Site 0042), Cincinnati
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
招募中2 期
- Oncology Hematology Care, Inc, Cincinnati
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
招募中3 期
- St Elizabeth Healthcare, Edgewood · 距离 8 英里
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
招募中1/2 期
- Christ Hospital, Cincinnati
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
招募中3 期
- University of Cincinnati Medical Center ( Site 0090), Cincinnati
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Cincinnati Children's Hospital Medical Center, Cincinnati
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- St. Elizabeth Healthcare, Edgewood · 距离 8 英里
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
招募中
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- 以及另外 3 项
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
招募中3 期
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- 以及另外 1 项
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
招募中1/2 期
- Oncology Hematology Care Primary, Cincinnati
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
招募中2/3 期
- St. Elizabeth Medical Center, Edgewood · 距离 8 英里
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
招募中2 期
- St. Elizabeth Medical Center - Edgewood /ID# 272113, Edgewood · 距离 8 英里
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
招募中3 期
- University of Cincinnati Medical Center, Cincinnati
- TriHealth Cancer Institute - Good Samaritan Hospital, Cincinnati
- TriHealth Cancer Institute- Thomas Comprehensive Care Center, Cincinnati
- 以及另外 1 项
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Cincinnati
其他城市的 卵巢癌试验
- Houston, TX89 项研究
- New York City, NY69 项研究
- Boston, MA61 项研究
- Los Angeles, CA50 项研究
- Nashville, TN49 项研究
- Arlington, VA46 项研究
- Philadelphia, PA44 项研究
- Columbus, OH39 项研究
- St. Louis, MO38 项研究
- Chicago, IL36 项研究
- San Antonio, TX31 项研究
- Cleveland, OH30 项研究
Cincinnati的其他研究
- 非小细胞肺癌35 项研究
- 癌症（所有类型）27 项研究
- 乳腺癌25 项研究
- 心力衰竭24 项研究
- 结直肠癌21 项研究
- 急性髓系白血病20 项研究
- 转移性癌症20 项研究
- 肺癌19 项研究
- 肥胖症19 项研究
- 前列腺癌18 项研究
- 多发性骨髓瘤17 项研究
- 黑色素瘤17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。